查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601611

病毒疫苗市场规模、占有率、预测、趋势分析：按形式类型、给药途径、方法、适应症、包装 - 2031 年全球预测

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form Type, Route of Administration, Approach, Indication, Packaging - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 239 Pages | 商品交期: 最快1-2个工作天内

价格

到2031年，病毒疫苗市场预计将达到641.8亿美元，2024年至2031年的复合年增长率为9.3%。

病毒疫苗或病毒载体疫苗使用病毒载体将遗传物质引入宿主体内，诱发免疫反应，对抗或预防病毒感染。

该市场的成长是由政府对免疫计划的兴趣日益浓厚、疫苗管理技术进步以及在手术和治疗中使用灭活疫苗推动的。然而，疫苗开发成本高、生产疫苗所需时间长，限制了市场的成长。

此外，对治疗性疫苗的日益关注、疫苗中佐剂的使用增加、新兴市场的增长前景以及稳定且节能的超低温冰箱的开发预计将为市场参与者带来增长机会。然而，产品召回和疫苗取得不足是影响市场成长的主要挑战。

该报告还对主要公司的产品组合和地理分布以及过去三到四年采取的主要成长策略进行了全面评估。作为最近的趋势，病毒疫苗市场经历了几次有机和无机的策略发展。本报告介绍的主要公司概况包括Pfizer Inc.（美国）、GlaxoSmithKline plc（英国）、AstraZeneca plc （英国）、CSL Limited（澳洲）、Merck & Co., Inc. （美国）、Sanofi （法国）、Sinovac Biotech Ltd.（中国）、Moderna, Inc.（美国）、Valneva SE（法国）、Dynavax Technologies Corporation（美国）、EMERGENT BIOSOLUTIONS INC.（美国）、Johnson &Johnson（美国）、Bharat Biotech Ltd.（印度）、Serum Institute.（印度）、Serum Institute of India Pvt.（印度）。

疫苗中佐剂的使用增加

传统的减毒疫苗已被证明对多种适应症有效，包括天花、麻疹和小儿麻痹。然而，这些疫苗通常会带来副作用，例如发烧、皮疹和疫苗引起的感染。此外，规模化生产和疫苗稳定性问题也是重大挑战。为了解决这些问题，人们开发了佐剂疫苗来刺激强大的免疫反应。

佐剂疫苗仅含有一小部分病原体，可降低免疫原性并最大限度地减少副作用。疫苗中的佐剂发挥多种作用，包括：

  • 透过施用纯形式的抗原来引发针对抗原的免疫反应。
  • 有利于一次性接种疫苗并降低疫苗接种成本。
  • 增强免疫功能低下患者的免疫反应。

直到最近，含铝佐剂仍被认为是与其他佐剂进行比较的黄金标准。然而，最近的进展改善了这些佐剂的物理、化学和生物特性，减少了人类的过敏反应、致癌性、致畸性和毒性。辅助系统也进行了各种改进。例如，基于水包油乳液的佐剂因其有效且有前景的结果而被开发供人类使用。此外，病毒体疫苗专为流感治疗而设计，可提供功效、品质和持久的免疫反应。正在进行的研究重点是选择最佳佐剂，例如经典佐剂、免疫刺激剂或其组合，以提高疫苗功效。因此，佐剂研究和利用的进步正在为疫苗製造商创造新的成长机会。

在本报告调查的形式中，冷冻干燥疫苗领域预计将在2024年创下病毒疫苗市场最高复合年增长率11.1%。冷冻干燥病毒疫苗透过冷冻干燥过程储存，可去除多余的水分，提高稳定性，延长保质期并方便运输。这些疫苗通常用于预防黄热病、麻疹、腮腺炎、德国麻疹和其他病毒性疾病等感染，并具有提高稳定性和运输能力等优点。

在本报告调查的疫苗类型中，病毒载体疫苗领域预计在2024年病毒疫苗市场的复合年增长率最高为17%。病毒载体疫苗使用基因改造病毒将遗传物质引入细胞，促使它们产生触发免疫反应的病毒蛋白。这些疫苗具有多种优势，包括强大的免疫反应、快速开发和可扩展性、广泛的功效以及多价疫苗的可能性。

在本报告调查的方法中，预防性疫苗领域预计将在 2024 年创下病毒疫苗市场最高复合年增长率。这一增长是由慢性病和传染病患者病率不断上升、公众疫苗接种意识增强以及免疫规划扩大等因素所推动的。例如，2024 年 2 月，印度联邦财政和企业事务部长在 Viksit Bharat 2047 运动下提出了一项疫苗接种计划，旨在预防 9 至 14 岁女孩患子宫颈癌。

在本报告调查的适应症中，癌症领域预计将在2024年创下病毒疫苗市场最高的复合年增长率，达到24.1%。据GLOBOCAN称，2022年将有2,000万新报告癌症病例，预计2030年将增加至2,410万例。癌症盛行率的不断上升凸显了对减少人类痛苦和经济负担的预防技术的需求。疫苗在癌前病变和癌症的一级预防以及减少已接受治疗的患者復发的二级预防中发挥着重要作用。

在本报告调查的给药途径中，预计到 2024 年，肌肉注射将占据病毒疫苗市场的最大占有率。优选肌肉注射，即将疫苗注射到患者的肌肉中，因为其安全性、耐受性、与各种类型疫苗的相容性以及引发强烈免疫反应的能力。

在本报告研究的包装类型中，小瓶包装预计将在 2024 年病毒疫苗市场达到最高复合年增长率。塑胶或玻璃瓶是用于包装液体或粉末药物的小容器。小瓶为病毒疫苗提供了一个保护环境，透过保护它们免受水分、光线和污染等外部因素的影响，帮助保持稳定性和有效性。

在本报告研究的地区中，亚太地区的病毒疫苗市场复合年增长率预计最高，达 10.2%。促成这一增长的主要因素包括传染患者病率的增加、公众对疫苗和免疫接种意识的提高、政府举措、高医疗保健支出以及可支配收入的增加。例如，2024年4月，沃克哈特医院（印度）针对所有年龄层的人启动了免疫计划，以强调疫苗接种的重要性。

调查范围：

病毒疫苗市场：依形式

  • 液体疫苗
  • 冷冻干燥疫苗

病毒疫苗市场：依疫苗类型划分

  • 次单位疫苗和结合疫苗
  • 活疫苗
  • 灭活​​疫苗
  • mRNA疫苗
  • 病毒载体疫苗
  • 类毒素疫苗
  • 联合疫苗

病毒疫苗市场：依给药途径划分

  • 肌肉注射 (IM)
  • 皮下注射 (SC)
  • 口头
  • 其他给药途径

（其他病毒包括诺罗病毒、DNA病毒）

病毒疫苗市场：依方法划分

  • 预防性疫苗
  • 治疗性疫苗

病毒疫苗市场：依适应症划分

  • 流感
  • 人类乳突病毒 (HPV)
  • 轮状病毒
  • 小儿麻痹
  • 肝炎
  • 癌症
  • 其他适应症

（其他适应症包括水痘、带状疱疹疫苗、小球藻、严重急性呼吸道症候群、狂犬病等）

病毒疫苗市场：依包装划分

  • 小瓶
  • 预灌封注射器

病毒疫苗市场：依地区划分

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 瑞士
    • 爱尔兰
    • 丹麦
    • 比利时
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 中东/非洲

目录

第一章简介

第二章研究方法

第 3 章执行摘要

第 4 章市场洞察

  • 市场概览
  • 影响市场成长的因素
    • 促进因素
      • 政府对疫苗接种计划的兴趣增加
      • 疫苗接种技术的进步
    • 阻碍因素
      • 疫苗开发成本高
      • 延长疫苗生产时间
    • 机会
      • 越来越多关注治疗性疫苗
      • 疫苗中佐剂的使用增加
      • 新兴市场的成长前景
    • 课题
      • 产品系列
      • 无法充分取得疫苗
    • 主要趋势
      • 个人化疫苗与疫苗组学
      • 媒体与大众对疫苗接种的认识
  • 监理分析
  • 价格分析
  • 波特五力分析
  • 管道分析

第五章病毒疫苗市场评估：依形式

  • 摘要
  • 液体病毒疫苗
  • 冷冻干燥病毒疫苗

第六章病毒疫苗市场：依疫苗类型

  • 摘要
  • mRNA疫苗
  • 次单位疫苗和结合疫苗
  • 活疫苗
  • 灭活​​疫苗
  • 病毒载体/疫苗
  • 联合疫苗

第七章病毒疫苗市场评估：依给药途径

  • 摘要
  • 肌肉注射 (IM)
  • 皮下注射 (SC)
  • 口头
  • 其他给药途径

第八章病毒疫苗市场评估：依方法

  • 摘要
  • 预防性疫苗
  • 治疗性疫苗

第九章病毒疫苗市场评估：依适应症

  • 摘要
  • 流感
  • 人类乳突病毒 (HPV)
  • 轮状病毒
  • 小儿麻痹
  • 肝炎
  • 癌症
  • 其他适应症

第十章病毒疫苗市场评估：依包装

  • 摘要
  • 小瓶
  • 预灌封注射器

第十一章冠状病毒疾病

  • 新冠肺炎 (COVID-19)：概述
  • 冠状病毒流行情况
  • 新冠肺炎 (COVID-19) 市场评估

第十二章病毒疫苗市场评估：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 瑞士
    • 爱尔兰
    • 丹麦
    • 比利时
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 中东/非洲

第十三章竞争态势

  • 简介
  • 主要成长策略
  • 竞争基准测试
  • 竞争对手仪表板
    • 行业领导者
    • 市场差异化因素
    • 领先企业
    • 新兴公司
  • 市占率分析

第十四章公司简介

  • Pfizer Inc.
  • Glaxo Smith Kline plc
  • AstraZeneca plc
  • CSL Limited
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Johnson & Johnson
  • Emergent Biosolutions Inc.
  • Bharat Biotech Ltd.
  • Sinovac Biotech Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Dynavax Technologies Corporation
  • Valneva SE

第15章附录

Product Code: MRHC - 1041237

Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031

According to a new market research report, 'Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging - Global Forecast to 2031', published by Meticulous Research(R), the viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031.

Viral vaccines or viral vector vaccines use a viral vector to deliver genetic material into the host to elicit an immune response to fight or protect against viral infections.

The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.

Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market's growth.

The report also includes an extensive assessment of the leading players' product portfolio and geographic presence and the key growth strategies adopted by them over the past three to four years. In recent years, the viral vaccines market has witnessed several organic and inorganic strategic developments. The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).

Increasing Use of Adjuvants in Vaccines

Conventional live-attenuated vaccines have proven effective for various indications, such as smallpox, measles, and polio, in most cases. However, these vaccines often come with side effects, including fever, rashes, and vaccine-derived infections. Additionally, large-scale production and issues related to vaccine consistency present significant challenges. To address these issues, adjuvant vaccines, which stimulate robust immune responses, were developed.

Adjuvant vaccines contain only a small part of the pathogen, which helps reduce immunogenicity and minimizes side effects. Adjuvants in vaccines serve various purposes, including:

  • Initiating the immune response to antigens by delivering them in their native form.
  • Facilitating single-step vaccination, thereby reducing vaccination costs.
  • Enhancing immune responses in immunocompromised individuals.

Until recently, aluminum-containing adjuvants were considered the gold standard for comparing other adjuvants. However, recent advancements have improved the physical, chemical, and biological properties of these adjuvants, reducing hypersensitivity reactions, carcinogenicity, teratogenicity, and toxicity in humans. Various modifications to adjuvant systems have also been made. For instance, oil-in-water emulsion-based adjuvants have been developed for human use due to their effective and promising results. Additionally, virosome vaccines have been specifically designed for influenza treatment, offering effectiveness, quality, and long-lasting immune responses. Ongoing research is focused on selecting the best adjuvants-whether classical adjuvants, immunostimulants, or combinations-to enhance vaccine efficacy. As a result, advancements in adjuvant research and utilization present new growth opportunities for vaccine manufacturers.

The viral vaccines market is segmented by Form (Liquid Vaccines, Lyophilized Vaccines), Vaccine Type (mRNA Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines), Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, and Other Routes of Administration), Approach (Preventive Vaccines, Therapeutic Vaccines), Indication (Influenza, Human Papilloma Virus (HPV), Rotavirus, Poliomyelitis (Polio), Hepatitis, Cancer, and Other Indications), Packaging (Vials, Prefilled Syringes) and Geography.

Among the forms studied in this report, in 2024, the lyophilized vaccines segment is slated to register the highest CAGR of 11.1% of the viral vaccines market. Lyophilized viral vaccines are preserved through a freeze-drying process that removes excess water, enhancing their stability, extending shelf life, and making transportation easier. These vaccines are commonly used to prevent infections such as yellow fever, measles, mumps, rubella, and other viral diseases, offering advantages such as improved stability and transportability.

Among the vaccine types studied in this report, in 2024, the viral vector vaccines segment is slated to register the highest CAGR of 17% of the viral vaccines market. Viral vector vaccines use modified viruses to deliver genetic material into cells, prompting them to produce viral proteins that trigger an immune response. These vaccines offer several benefits, including a strong immune response, rapid development and scalability, broad effectiveness, and the potential for creating multivalent vaccines.

Among the approaches studied in this report, in 2024, the preventive vaccines segment is slated to register the highest CAGR of the viral vaccines market. This growth is driven by factors such as the increasing prevalence of chronic and infectious diseases, rising public awareness of immunization, and the expansion of immunization programs. For instance, in February 2024, the Union Minister for Finance & Corporate Affairs of India proposed a vaccination program under the Viksit Bharat by 2047 campaign aimed at preventing cervical cancer in girls aged 9 to 14.

Among the indications studied in this report, in 2024, the cancer segment is slated to register the highest CAGR of 24.1% of the viral vaccines market. Cancer prevalence is rising globally; according to GLOBOCAN, 20.0 million new cancer cases were reported in 2022, with this number projected to increase to 24.1 million by 2030. The growing prevalence of cancer highlights the need for preventive techniques to reduce human suffering and financial burdens. Vaccines play a crucial role in first-line prevention of premalignant conditions and cancer, as well as in secondary prevention for patients who have undergone curative treatments to reduce recurrence.

Among the routes of administration studied in this report, in 2024, the intramuscular segment is expected to account for the largest share of the viral vaccines market. The IM route, which involves administering vaccines into a patient's muscles, is preferred due to its ability to elicit a strong immune response, along with its safety, tolerability, and compatibility with various vaccine types.

Among the packaging types studied in this report, in 2024, the vials segment is slated to register the highest CAGR of the viral vaccines market. Vials, made from plastic or glass, are small containers used to package liquid or powdered medications. They provide a protective environment for viral vaccines, helping to maintain stability and efficacy by shielding the vaccines from external factors like moisture, light, and contamination.

Among the regions studied in this report, Asia-Pacific is slated to register the highest CAGR of 10.2% of the viral vaccines market. This growth is primarily attributed to the increasing prevalence of infectious diseases, growing public awareness of vaccines and immunization, government initiatives, high healthcare expenditure, and rising disposable incomes. For instance, in April 2024, Wockhardt Hospitals (India) launched an immunization program aimed at people of all age groups to emphasize the importance of vaccination.

Scope of the Report:

Viral Vaccines Market-by Form

  • Liquid Vaccines
  • Lyophilized Vaccines

Viral Vaccines Market-by Vaccine Type

  • Subunit & Conjugate Vaccines
  • Live-attenuated Vaccines
  • Inactivated Vaccines
  • mRNA Vaccines
  • Viral Vector Vaccines
  • Toxoid Vaccines
  • Combination Vaccines

Viral Vaccines Market-by Route of Administration

  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Oral
  • Other Routes of Administration

(Other virus types include norovirus and DNA viruses)

Viral Vaccines Market-by Approach

  • Preventive Vaccines
  • Therapeutic Vaccines

Viral Vaccines Market-by Indication

  • Influenza
  • Human Papilloma Virus (HPV)
  • Rotavirus
  • Poliomyelitis (Polio)
  • Hepatitis
  • Cancer
  • Other Indications

(Other indications include varicella, herpes zoster vaccines, chlorella, severe acute respiratory syndrome, and rabies diseases)

Viral Vaccines Market-by Packaging

  • Vials
  • Prefilled Syringes

Viral Vaccines Market-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Switzerland
    • Ireland
    • Denmark
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection and Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders From The Industry
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Increasing Government Focus on Immunization Programs
      • 4.2.1.2. Technological Advancements in Vaccine Administration
    • 4.2.2. Restraints
      • 4.2.2.1. High Costs of Vaccine Development
      • 4.2.2.2. Long Timelines of Vaccine Manufacturing
    • 4.2.3. Opportunities
      • 4.2.3.1. Growing Focus on Therapeutic Vaccines
      • 4.2.3.2. Increasing Use of Adjuvants in Vaccines
      • 4.2.3.3. Growth Prospects in Emerging Markets
    • 4.2.4. Challenges
      • 4.2.4.1. Product Recalls
      • 4.2.4.2. Inadequate Access to Vaccines
    • 4.2.5. Key Trends
      • 4.2.5.1. Personalized Vaccines and Vaccinomics
      • 4.2.5.2. Media and Public Awareness Regarding Immunization
  • 4.3. Regulatory Analysis
  • 4.4. Pricing Analysis
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Buyers
    • 4.5.2. Bargaining Power of Suppliers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Pipeline Analysis

5. Viral Vaccines Market Assessment-by Form

  • 5.1. Overview
  • 5.2. Liquid Viral Vaccines
  • 5.3. Lyophilized Viral Vaccines

6. Viral Vaccines Market-by Vaccine Type

  • 6.1. Overview
  • 6.2. mRNA Vaccines
  • 6.3. Subunit & Conjugate Vaccines
  • 6.4. Live-attenuated Vaccines
  • 6.5. Inactivated Vaccines
  • 6.6. Viral Vector Vaccines
  • 6.7. Combination Vaccines

7. Viral Vaccines Market Assessment-by Route of Administration

  • 7.1. Overview
  • 7.2. Intramuscular (IM)
  • 7.3. Subcutaneous (SC)
  • 7.4. Oral
  • 7.5. Other Routes of Administration

8. Viral Vaccines Market Assessment-by Approach

  • 8.1. Overview
  • 8.2. Preventive Vaccines
  • 8.3. Therapeutic Vaccines

9. Viral Vaccines Market Assessment-by Indication

  • 9.1. Overview
  • 9.2. Influenza
  • 9.3. Human Papillomavirus (HPV)
  • 9.4. Rotavirus
  • 9.5. Poliomyelitis (Polio)
  • 9.6. Hepatitis
  • 9.7. Cancer
  • 9.8. Other Indications

10. Viral Vaccines Market Assessment-by Packaging

  • 10.1. Overview
  • 10.2. Vials
  • 10.3. Prefilled Syringes

11. Coronavirus Disease

  • 11.1. COVID-19: Overview
  • 11.2. Coronavirus Prevalence
  • 11.3. COVID-19 Market Assessment

12. Viral Vaccines Market Assessment-by Geography

  • 12.1. Overview
  • 12.2. North America
    • 12.2.1. U.S.
    • 12.2.2. Canada
  • 12.3. Europe
    • 12.3.1. Germany
    • 12.3.2. U.K.
    • 12.3.3. France
    • 12.3.4. Italy
    • 12.3.5. Spain
    • 12.3.6. Switzerland
    • 12.3.7. Ireland
    • 12.3.8. Denmark
    • 12.3.9. Belgium
    • 12.3.10. Rest of Europe
  • 12.4. Asia-Pacific
    • 12.4.1. Japan
    • 12.4.2. China
    • 12.4.3. India
    • 12.4.4. South Korea
    • 12.4.5. Rest of Asia-Pacific
  • 12.5. Latin America
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Middle East & Africa

13. Competitive Landscape

  • 13.1. Introduction
  • 13.2. Key Growth Strategies
  • 13.3. Competitive Benchmarking
  • 13.4. Competitive Dashboard
    • 13.4.1. Industry Leaders
    • 13.4.2. Market Differentiators
    • 13.4.3. Vanguards
    • 13.4.4. Emerging Companies
  • 13.5. Market Share Analysis

14. Company Profiles

  • 14.1. Pfizer Inc.
  • 14.2. Glaxo Smith Kline plc
  • 14.3. AstraZeneca plc
  • 14.4. CSL Limited
  • 14.5. Merck & Co., Inc.
  • 14.6. Moderna, Inc.
  • 14.7. Johnson & Johnson
  • 14.8. Emergent Biosolutions Inc.
  • 14.9. Bharat Biotech Ltd.
  • 14.10. Sinovac Biotech Ltd.
  • 14.11. Sanofi
  • 14.12. Serum Institute of India Pvt. Ltd.
  • 14.13. Dynavax Technologies Corporation
  • 14.14. Valneva SE

15. Appendix

  • 15.1. Available Customization
  • 15.2. Related Reports

LIST OF TABLES

  • Table 1 Estimated Number of Malaria Cases in Regions with Emerging Countries, 2022 (in Thousands)
  • Table 2 Number of People Living with HIV, by Region, 2022 (in Million)
  • Table 3 Key Government Agencies Regulating Vaccines
  • Table 4 Average Selling Prices of Key Vaccines, by Region (USD/UNIT)
  • Table 5 Viral Vaccines: Pipeline Analysis
  • Table 6 Global Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 7 Global Liquid Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 8 Companies Offering Lyophilized Viral Vaccines
  • Table 9 Global Lyophilized Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 11 Companies Offering mRNA Vaccines
  • Table 12 Global mRNA Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Companies Offering Subunit and Conjugate Vaccines
  • Table 14 Global Subunit & Conjugate Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Companies Offering Live-Attenuated Vaccines
  • Table 16 Global Live-Attenuated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Key Companies Offering Inactivated Vaccines
  • Table 18 Global Inactivated Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Global Viral Vector Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Key Companies Offering Combination Vaccines
  • Table 21 Global Combination Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 23 Intramuscular Sites For Vaccine Administration, by Age Group
  • Table 24 Global Intramuscular Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Subcutaneous Sites For Vaccine Administration, by Age Group
  • Table 26 Global Subcutaneous Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Key Companies Offering Oral Viral Vaccines
  • Table 28 Global Oral Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Viral Vaccines Market for Other Routes of Administration, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 31 Global Preventive Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global Therapeutic Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 34 Global Viral Vaccines Market For Influenza, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Viral Vaccines Market For Human Papillomavirus (HPV), by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Viral Vaccines Market For Rotavirus, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Viral Vaccines Market For Poliomyelitis, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Viral Vaccines Market For Hepatitis, by Country/Region, 2022-2031 (USD Million)
  • Table 39 Global NUMBER of New Cancer Cases, 2022-2030
  • Table 40 Global Viral Vaccines Market For Cancer, by Country/Region, 2022-2031 (USD Million)
  • Table 41 Global Viral Vaccines Market For Other Indications, by Country/Region, 2022-2031 (USD Million)
  • Table 42 Global Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 43 Global Viral Vaccine Vials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 44 Global Prefilled Viral Vaccine Syringes Market, by Country/Region, 2022-2031 (USD Million)
  • Table 45 COVID-19: Overview
  • Table 46 Coronavirus Confirmed Cases, by Region (As of April 2024)
  • Table 47 Global Viral Vaccines Market FOR COVID-19, by Country/Region, 2022-2031 (USD Million)
  • Table 48 Global Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 49 North America: Viral Vaccines Market, by Country, 2022-2031 (USD Million)
  • Table 50 North America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 51 North America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 52 North America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 53 North America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 54 North America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 55 North America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 56 U.S.: Accelerated Approval Dates of Vaccines By The U.S. FDA
  • Table 57 U.S.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 58 U.S.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 59 U.S.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 60 U.S.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 61 U.S.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 62 U.S.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 63 Canada: Influenza Cases, 2023-2024, Week 1-34
  • Table 64 Canada: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 65 Canada: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 66 Canada: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 67 Canada: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 68 Canada: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 69 Canada: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 70 Europe: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 71 Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 72 Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 73 Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 74 Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 75 Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 76 Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 77 Germany: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 78 Germany: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 79 Germany: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 80 Germany: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 81 Germany: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 82 Germany: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 83 U.K.: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 84 U.K.: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 85 U.K.: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 86 U.K.: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 87 U.K.: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 88 U.K.: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 89 France: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 90 France: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 91 France: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 92 France: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 93 France: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 94 France: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 95 Italy: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 96 Italy: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 97 Italy: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 98 Italy: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 99 Italy: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 100 Italy: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 101 Spain: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 102 Spain: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 103 Spain: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 104 Spain: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 105 Spain: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 106 Spain: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 107 Switzerland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 108 Switzerland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 109 Switzerland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 110 Switzerland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 111 Switzerland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 112 Switzerland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 113 Ireland: Number of Infectious Diseases Notifications (2019-2023)
  • Table 114 Ireland: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 115 Ireland: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 116 Ireland: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 117 Ireland: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 118 Ireland: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 119 Ireland: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 120 Denmark: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 121 Denmark: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 122 Denmark: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 123 Denmark: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 124 Denmark: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 125 Denmark: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 126 Belgium: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 127 Belgium: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 128 Belgium: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 129 Belgium: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 130 Belgium: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 131 Belgium: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 132 Rest of Europe: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 133 Rest of Europe: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 134 Rest of Europe: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 135 Rest of Europe: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 136 Rest of Europe: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 137 Rest of Europe: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 138 Asia-Pacific: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 139 Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 140 Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 141 Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 142 Asia-Pacific: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 143 Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 144 Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 145 Japan: Key Macroindicators & Microindicators
  • Table 146 Japan: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 147 Japan: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 148 Japan: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 149 Japan: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 150 Japan: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 151 Japan: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 152 China: Key Macroindicators & Microindicators
  • Table 153 China: Key Immunization Indicators
  • Table 154 China: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 155 China: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 156 China: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 157 China: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 158 China: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 159 China: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 160 India: Key Macroindicators & Microindicators
  • Table 161 India: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 162 India: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 163 India: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 164 India: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 165 India: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 166 India: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 167 South Korea: Key Macroindicators & Microindicators
  • Table 168 South Korea: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 169 South Korea: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 170 South Korea: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 171 South Korea: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 172 South Korea: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 173 South Korea: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 174 Bangladesh: Key Immunization Indicators
  • Table 175 Nepal: Key Immunization Indicators
  • Table 176 Rest of Asia-Pacific: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 177 Rest of Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 178 Rest of Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 179 Rest of Asia-Pacific: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 180 Rest of Asia-Pacific: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 181 Latin America: Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
  • Table 182 Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 183 Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 184 Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 185 Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 186 Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 187 Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 188 Brazil: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 189 Brazil: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 190 Brazil: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 191 Brazil: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 192 Brazil: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 193 Brazil: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 194 Mexico: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 195 Mexico: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 196 Mexico: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 197 Mexico: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 198 Mexico: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 199 Mexico: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 200 Rest of Latin America: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 201 Rest of Latin America: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 202 Rest of Latin America: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 203 Rest of Latin America: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 204 Rest of Latin America: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 205 Rest of Latin America: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 206 Middle East & Africa: Viral Vaccines Market, by Form, 2022-2031 (USD Million)
  • Table 207 Middle East & Africa: Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
  • Table 208 Middle East & Africa: Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
  • Table 209 Middle East & Africa: Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
  • Table 210 Middle East & Africa: Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
  • Table 211 Middle East & Africa: Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
  • Table 212 Recent Developments, by Company (2021-2024)

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for this Study
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6 Market Sizing and Growth Forecast Approaches
  • Figure 7 Global Viral Vaccines Market, by Indication, 2024 Vs.2031 (USD Million)
  • Figure 8 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
  • Figure 11 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
  • Figure 12 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
  • Figure 13 Global Viral Vaccines Market, by Geography
  • Figure 14 Impact Analysis of Market Dynamics
  • Figure 15 Porter's Five Forces Analysis
  • Figure 16 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
  • Figure 17 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
  • Figure 18 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
  • Figure 19 Global Viral Vaccines Market, by Approach, 2024 VS. 2031 (USD Million)
  • Figure 20 Global Viral Vaccines Market, by Indication, 2024 VS. 2031 (USD Million)
  • Figure 21 Global Viral Vaccines Market, by Packaging, 2024 VS. 2031 (USD Million)
  • Figure 22 Global Viral Vaccines Market, by GEOGRAPHY, 2024 VS. 2031 (USD Million)
  • Figure 23 North America: Viral Vaccines Market Snapshot
  • Figure 24 Europe: Viral Vaccines Market Snapshot
  • Figure 25 Asia-Pacific: Viral Vaccines Market Snapshot
  • Figure 26 Number of Cases Reported for Dengue, 2019-2023
  • Figure 27 Latin America: Viral Vaccines Market Snapshot
  • Figure 28 Saudi Arabia Viral Vaccination Coverage (2023)
  • Figure 29 Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 30 Viral Vaccines Market: Competitive Benchmarking (Based On Indications)
  • Figure 31 Viral Vaccines Market: Competitive Benchmarking (BASED ON Region)
  • Figure 32 Competitive Dashboard: Viral Vaccines Market
  • Figure 33 Market Share Analysis: Viral Vaccines Market (with Covid-19 Vaccines), 2023
  • Figure 34 Market Share Analysis: Viral Vaccines Market (Without Covid-19 Vaccines), 2023
  • Figure 35 Pfizer Inc.: Financial Snapshot (2023)
  • Figure 36 Glaxo Smith Kline Plc: Financial Overview (2023)
  • Figure 37 AstraZeneca Plc: Financial Overview (2023)
  • Figure 38 CSL LIMITED: Financial Overview (2024)
  • Figure 39 Merck & Co., Inc.: Financial Overview (2023)
  • Figure 40 Moderna, Inc.: Financial Snapshot (2023)
  • Figure 41 Johnson & Johnson: Financial Snapshot (2023)
  • Figure 42 Emergent Biosolutions Inc.: Financial Snapshot (2023)
  • Figure 43 Sinovac Biotech Ltd.: Financial Overview (2023)
  • Figure 44 Sanofi: Financial Overview (2023)
  • Figure 45 Dynavax Technologies Corporation: Financial Snapshot (2023)
  • Figure 46 Valneva SE: Financial Snapshot (2023)